Sunshine Biopharma (SBFM) Common Equity (2010 - 2026)

Sunshine Biopharma has reported Common Equity for 17 years, with the latest figure at $21.5 million in Q1 2026.

• For the quarter ending Q1 2026, Common Equity fell 5.22% year-over-year to $21.5 million; the trailing twelve-month figure through Mar 2026 stood at $21.5 million (down 5.22% YoY), and the FY2025 full-year result was $23.0 million, down 1.97% from the prior year.
• Common Equity for Q1 2026 stood at $21.5 million, down from $23.0 million in the prior quarter.
• The five-year high for Common Equity was $41.9 million in Q2 2022, with the low at $13.3 million in Q1 2022.
• Historically, Common Equity has averaged $24.5 million across 5 years, with a median of $23.1 million in 2023.
• Annual changes were most pronounced in 2022 — Common Equity soared 10117.97% — and 2023, when it tumbled 45.61%.
• Sunshine Biopharma's Common Equity stood at $21.6 million in 2022, then dropped by 1.94% to $21.2 million in 2023, then advanced by 10.81% to $23.5 million in 2024, then retreated by 1.97% to $23.0 million in 2025, then slipped by 6.61% to $21.5 million in 2026.
• The last three Common Equity figures came in at $21.5 million (Q1 2026), $23.0 million (Q4 2025), and $24.2 million (Q3 2025), per Business Quant data.